Current treatment options for lung disease caused by Mycobacterium abscessus complex infections have limited effectiveness. To maximize the use of existing antibacterials and to help inform regimen design treatment, we assessed in vitro bactericidal activity single drugs against actively multiplying net nonreplicating M. populations nutrient-rich nutrient-starvation conditions, respectively. As...

The review presents up-to-date data from 88 publications devoted to the short-course regimens of multiple drug resistant tuberculosis treatment and describes characteristics most effective drugs – bedaquiline, linezolid, delamanid, clofazimine. Information is also provided on additional properties drugs, i.e. modulation key immune response immunometabolic processes that underlie a new approach ...

Recently, the World Health Organization (WHO) has released a revised definition of extensively drug-resistant (XDR) tuberculosis (TB) that should be used for clinical and surveillance purposes starting from 1 January, 2021 [1, 2]. The previous XDR-TB was TB is resistant to any fluoroquinolone (levofloxacin and/or moxifloxacin) at least one three second-line injectable drugs (SLIs: capreomycin, ...

Emergence of drug resistant tuberculosis like multi drug resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB) and totally drug resistant tuberculosis (TDR-TB) has created a new challenge to fight against these bad bugs of Mycobacterium tuberculosis. Repurposing and revival of the drugs are the new trends/options to combat these worsen situations of tuberculosis in t...

The Neglected Tropical Disease Voucher Program is a Congressionally-mandated program intended to promote approval of products for tropical diseases because it provides spectacular financial compensation consequent to FDA approval of a priority product. Three drug approvals-artemether/lumifantrine for malaria, bedaquiline for multidrug resistant tuberculosis, miltefosine for leishmaniasis-have r...